Arena's CEO steps down; Sarepta raises $127M;

@FierceBiotech:  After a $191M IPO, Adaptimmune buys a new cancer R&D outpost. More | Follow @FierceBiotech

@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, UK. Event | Follow @JohnCFierce

@DamianFierce: Yes, good fun, my hip-hop peers, but what's REALLY wack is chronic obstructive pulmonary disease. | Follow @DamianFierce

> Arena Pharmaceuticals ($ARNA) CEO Jack Lief is retiring "at the request of the board," the company said, leaving the drug developer as it struggles to find a market for its obesity treatment. More

> Sarepta Therapeutics ($SRPT) raised $127 million in a stock offering, planning to put the money toward its ongoing development of a drug for Duchenne muscular dystrophy. News

> Akebia Therapeutics ($AKBA) is blueprinting a Phase III trial for its kidney disease drug after receiving feedback from the FDA and European Medicines Agency. The company expects to launch a late-stage program later this year. Item

Medical Device News

@FierceMedDev: Cancer Genetics makes strides in $14M deal for Response Genetics. FierceDiagnostics article | Follow @FierceMedDev

@EmilyWFierce: ICYMI: Want to get a warning letter from OPDP? Omit drug risks from your promos. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Story

> FDA orders postmarket studies from trio of duodenoscope makers as 'superbug' scare continues. Article

Pharma News

@FiercePharma: Something's got to give in India's pharma policy contradictions. More | Follow @FiercePharma

@EricPFierce: AmerisourceBergen injects itself into compounding industry with $2.5B deal for PharMEDium. Article | Follow @EricPFierce

@CarlyHFierce: Payers want new guidelines, more data before easing access to diabetes' CV star Jardiance. Story | Follow @CarlyHFierce

> Drug price hikes a tried-and-true strategy for who's who of Big Pharma. More

> Roche CEO: Big Data needs Big Pharma, and vice versa. News

Drug Delivery News

> Perrigo licenses Flamel's oral suspension delivery platform to develop additional OTC meds. More

> Novel catheter designed for rectal drug delivery wins CE mark. Article

> GSK obtains rights to inhaled nanoparticles made using Liquidia's PRINT platform. News

> Genisphere snags $4M to move its 3DNA platform into the clinic. Story

> Polymer microneedles embedded with cancer drugs degrade to treat skin carcinomas. More

Pharma Manufacturing News

> AmerisourceBergen lays out $2.5B for sterile compounder PharMEDium. Article

> Baxter recalls more saline, this time for potential mold contamination. Report

> India intends to establish drug testing labs in effort to boost quality. Item

> Hospira recalls more lidocaine with rust embedded in vials. Story

> Pfizer adding jobs to Ireland plant that had been slated to close. Article

Pharma Asia News

> JHL Biotech tests the waters on Taiwan's Emerging Stock Board. Item

> Something's got to give in India's pharma policy contradictions. More

> India considers drug testing labs in each state. Report

> TPP negotiators said to reach compromise on biologics. Story

> Japanese flu vaccine makers pump up prices 50%, drawing flak as peak season hits. Article

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.